1403/01/30
جهانبخش رئوف

جهانبخش رئوف

مرتبه علمی: استاد
ارکید:
تحصیلات: دکترای تخصصی
اسکاپوس:
دانشکده: دانشکده شیمی
نشانی:
تلفن: 01135302392

مشخصات پژوهش

عنوان
Downregulation of the WT1 gene expression via TMPyP4 stabilization of promoter G-quadruplexes in leukemia cells
نوع پژوهش
JournalPaper
کلیدواژه‌ها
WT1promoter . G-quadruplex stability . TMPyP4 .Downregulation of transcription Introduction
سال
2016
مجله TUMOR BIOLOGY
شناسه DOI
پژوهشگران Saeedeh Ghazaey Zidanloo ، Abasalt Hosseinzadeh Colagar ، Hossein Ayatollahi ، Jahan Bakhsh Raoof

چکیده

The WT1 gene is an important oncogene, and its overexpression is considered as an effective target for antican- cer therapy. Regulation of its gene transcription is one way for WT1-targeting drug design. Recently, in silico analysis of some oncogene promoters like WT1 showed some guanine- rich regions with the ability to form G-quadruplex structures. Ligands like 5,10,15,20-tetra(N-methyl-4-pyridyl)-porphine (TMPyP4) have predominant effect on G-quadruplex stabili- zation. The aim of this study was to understand the effect of TMPyP4 on WT1 gene transcription via stabilization of pro- moter G-quadruplexes.We examined the formation of newG- quadruplex motifs in WT1 promoter in the presence of TMPyP4. In order to understand the nature of its interaction withWT1 promoter quadruplexes, differential pulse voltamm- etry (DPV), circular dichroism(CD), polyacrylamide gel elec- trophoresis, electrophoretic mobility shift assay (EMSA), po- lymerase chain reaction (PCR) stop assays, and quantitative RT-PCR were performed. According to the results, the WT1 promoter can form stable intramolecular parallel G- quadruplexes. In addition, after 48 and 96 h of incubation,100 μM TMPyP4 reduced the WT1 transcription to 9 and 0.4 %, respectively, compare to control. We report that ligand-mediated stabilization of G-quadruplexes within the WT1 promoter can silence WT1 expression. This study might offer the basis for the reasonable design and improvement of new porphyrin derivatives as effective anti-leukemia agents for cancer therapy